Half‐Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand‐Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Brimonidine (Primary)
- Indications Erythrodysaesthesia
- Focus Therapeutic Use
- Acronyms BRIMOCAN
- 07 Jan 2019 Status changed from recruiting to discontinued.
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.
- 06 Jun 2017 New trial record